Pasithea Therapeutics Corp.

We are a clinical-stage biotechnology company focused on discovering, researching, and developing innovative treatments for RASopathies, MAPK pathway-driven tumors, and other diseases, including central nervous system (CNS) disorders. We are advancing a pipeline of two therapeutic product candidates. Our lead product candidate is PAS-004, a next-generation macrocyclic Mitogen-Activated Protein Kinase ("MEK") inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 ("MEK 1/2") for potential use in treating various RASopathies, including neurofibromatosis type 1 ("NF1"), and a number of MAPK pathway-driven tumors, such as those driven by BRAFv600 mutations and BRAF fusion tumors. It is also being developed for amyotrophic lateral sclerosis ("ALS") and other indications, including ETS2 driven diseases like inflammatory bowel disease ("IBD"), primary sclerosing cholangitis, and ankylosing spondylitis. MEK 1/2 are protein kinases involved in the mitogen-activated protein kinase, or MAPK pathway, which is important in cellular biology and a frequent target for drug discovery. The MAPK pathway drives cell proliferation, differentiation, survival, and other cellular functions, and its abnormal upregulation is critical for tumor formation and progression, fibrosis, and other diseases. MEK inhibitors block the activation of extracellular signal-regulated kinases ("ERK"), which can lead to cell death and inhibition of tumor growth. Existing MEK inhibitors approved by the U.S. Food and Drug Administration (the "FDA") are marketed for certain cancers and symptomatic, inoperable NF1-associated plexiform neurofibromas ("NF1-PN"). For NF1-PN, Koselugo (selumitinib) and Gomekli (mirdametinib) are FDA approved for adult and pediatric NF1-PN patients.